13.84USD-1.00%Mkt Cap: 850.58M USDP/E: —Last update: 2026-05-22
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap850.58M USD
Enterprise Value509.68M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-219.88M USD
Revenue/Share—
Last Price13.84 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees109
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.50
PEG—
EV/EBITDA-2.12
EV/Revenue—
P/S—
P/B2.35
EPS (TTM)-3.37
EPS (Forward)-2.54
52W Range
5.68074% of range16.74
52W High16.74 USD
52W Low5.680 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-53.80%
ROA-49.04%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-175.75M USD
CapEx (TTM)49.00K USD
FCF Margin—
FCF Yield-12.09%
Net Debt-349.50M USD
Net Debt/EBITDA1.46
Balance Sheet
Debt/Equity0.01
Current Ratio10.28
Quick Ratio10.09
Book Value/Sh5.959 USD
Cash/Share5.726 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)31.45 USD
Target Range23.00 USD – 38.00 USD
# Analysts11
Ownership
Shares Out.61.46M
Float44.27M
Insiders0.45%
Institutions107.77%
Short Interest
Short Ratio12.5d
Short % Float20.31%
Short % Out.14.32%
Shares Short8.80M
Short (prev mo.)8.39M
Technical
SMA 5014.20 (-2.5%)
SMA 20010.77 (+28.4%)
Beta-0.09
S&P 52W Chg28.31%
Avg Vol (30d)883.48K
Avg Vol (10d)1.08M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—